...
首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Mesenchymal stromal cells loading curcumin-INVITE-micelles: A drug delivery system for neurodegenerative diseases
【24h】

Mesenchymal stromal cells loading curcumin-INVITE-micelles: A drug delivery system for neurodegenerative diseases

机译:间充质基质细胞加载姜黄素-邀请胶束:神经退行性疾病的药物输送系统

获取原文
获取原文并翻译 | 示例
           

摘要

This work reports on the formation of a carrier-in-carrier device for the systemic delivery and targeting of hydrophobic drugs mediated by micelle-loaded mesenchymal stromal cells (MSCs) (carrier-in-carrier) to be administered by intravenous injection. The innate ability of MSCs to reach injured tissues such as the central nervous system or other damaged tissues, is the key for the second order delivery and first order targeting. Inulin-D-alfa-tocopherol succinate micelles (INVITE M) are able to incorporate highly hydrophobic drugs and, due to their dimensions (approximate to 7 nm diameter), to penetrate the cell membrane easily and quickly. This study demonstrates that the curcumin loaded micelles (INVITE MC), sterilized by filtration, reached the maximum loading in MSCs in few minutes and that the loading was concentration-dependent. When "naked" curcumin was used, an evident cytotoxicity on MSCs was detected, while INVITE micelles protected them from this effect. Moreover, MSCs loaded with INVITE MC are able to release the entrapped drug. This study strongly supports the feasibility of the carrier-in-carrier approach for the therapy of selected diseases, i.e., this innovative drug delivery system will be proposed for the treatment of the amyotrophic lateral sclerosis (ALS). (C) 2014 Elsevier B.V. All rights reserved.
机译:这项工作报道了载体载体装置的形成,该载体载体装置用于通过静脉注射给药的由胶束负载的间充质基质细胞(MSC)(载体载体)介导的疏水性药物的全身递送和靶向。 MSC到达受伤组织(如中枢神经系统或其他受损组织)的先天能力,是第二阶段传递和第一阶段靶向的关键。菊粉-α-生育酚琥珀酸酯胶束(INVITE M)能够掺入高度疏水的药物,并且由于其尺寸(直径约7 nm),可以轻松快速地穿透细胞膜。这项研究表明,经过滤灭菌的姜黄素负载胶束(INVITE MC)在几分钟内达到了MSC中的最大负载,并且该负载是浓度依赖性的。当使用“裸”姜黄素时,可检测到对MSC的明显细胞毒性,而INVITE胶束可保护它们免受这种作用。而且,装载有INVITE MC的MSC能够释放被截留的药物。这项研究有力地支持了载体间结合法治疗某些疾病的可行性,即,将提出这种创新的药物递送系统来治疗肌萎缩性侧索硬化症(ALS)。 (C)2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号